TIGIT-Blocking Cancer Therapies
Can blocking TIGIT improve cancer immunotherapy outcomes, and which patients benefit?
Following this Track shows whether TIGIT blockade moves from a promising immune-checkpoint strategy toward consistent evidence of patient benefit. It also helps clarify where results may differ across cancer types.
Where it stands now
Main bottleneck
Current evidence contains reviews but no direct trial results, so it does not establish whether TIGIT blockade produces reliable clinical benefit or which patients are most likely to respond.
Watch next
Watch for reported clinical-trial results showing whether TIGIT blockade improves outcomes and safety compared with an appropriate control, with results reported by cancer type or patient group.
Progress timeline
How the evidence has changed over time.
2025 · 1 update
- Why did antibodies against an immune-cell brake fare differently in mice and people?Research note 3 of 3 · Source date 2025-07-15
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: What the TIGIT immune brake reveals in myeloma and other blood cancers
Previous expectation: TIGIT blockade might help people with blood cancers if its immune effects translated into safe clinical benefit.
What this study adds: This July 2025 review examines solid tumors and places disappointing human monotherapy results beside combination signals and antibody-design questions. Its stated study selection excludes blood cancers.
Current research note
2021 · 2 updates
- What does CD155 do to tumor cells and immune cells, and where might TIGIT blockade fit?Research note 1 of 3 · Source date 2021-01-19
- What the TIGIT immune brake reveals in myeloma and other blood cancersChanged directionResearch note 2 of 3 · Source date 2021-06-01
Since the previous research note · Changed direction
Track continuity
Since the previous research note: What does CD155 do to tumor cells and immune cells, and where might TIGIT blockade fit?
Previous expectation: TIGIT blockade might offer another treatment route for advanced solid tumors if it safely improved immune activity and patient outcomes.
What this study adds: The June 2021 review shifts attention to TIGIT in blood cancers, with separately identified earlier studies adding myeloma and myelodysplastic-syndrome observations. It does not test the earlier solid-tumor treatment forecast.
Current research note
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.